Showing 20 of 56 recruiting trials for “primary-pulmonary-lymphoma”
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Feb 2026View details ↗
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
👨⚕️ Hervé Pr. Ghesquieres, MD, HCL - Hôpital Lyon Sud - Service d'Hématologie - 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite - France📍 13 sites📅 Started Sep 2025View details ↗
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
👨⚕️ Christian Grommes, MD, Memorial Sloan Kettering Cancer Center📍 8 sites📅 Started Aug 2025View details ↗
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
👨⚕️ Narendranath Epperla, MD, MS, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT07188077 ↗
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
RecruitingNCT06755619 ↗
CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Aug 2024View details ↗
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Aug 2024View details ↗
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
👨⚕️ Yuliya Linhares, M.D., Miami Cancer Institute at Baptist Health, Inc.📍 1 site📅 Started Apr 2024View details ↗
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →